Pays: Australie
Langue: anglais
Source: Department of Health (Therapeutic Goods Administration)
piperacillin sodium, Quantity: 4.2 g (Equivalent: piperacillin, Qty 4 g); tazobactam sodium, Quantity: 0.54 g (Equivalent: tazobactam, Qty 0.5 g)
Alphapharm Pty Ltd
piperacillin sodium,tazobactam sodium
Injection, powder for
Excipient Ingredients:
Intravenous
1 Vial, 10 Vials, 10 Vial
(S4) Prescription Only Medicine
TAZOPIP is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta -lactamase producing organisms in the conditions as listed: 1. Lower respiratory tract infections 2. Urinary tract infections (complicated and uncomplicated). 3.Intra- abdominal infections. 4. Skin and skin structure infections. 5. Bacterial septicaemia. 6. Gynaecological infections. Children under the age of 12 years: In hospitalised children aged 2 to 12 years, TAZOPIP is indicated for the treatment of serious intra-abdominal infections. It has not been evaluated in this indication for paediatric patients below the age of 2 years. While TAZOPIP is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta -lactamase producing piperacillin-resistant organisms. Appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to TAZOPIP. Therapy with TAZOPIP may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta -lactamase producing organisms listed above. However, once these results become available, appropriate therapy should be continued. In serious infections, presumptive therapy with TAZOPIP may be initiated before susceptibility test results are available. Combination therapy with TAZOPIP and aminoglycosides may be used in the treatment of serious infections caused by Pseudomonas aeruginosa. Both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.
Visual Identification: White to off white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2009-09-21
TAZOPIP _Piperacillin (as sodium) and Tazobactam (as sodium) powder for injection_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about TAZOPIP. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking TAZOPIP against the benefits expected for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, TALK TO YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH YOUR MEDICINE. You may need to read it again. WHAT TAZOPIP IS USED FOR TAZOPIP contains the active ingredients piperacillin and tazobactam. This medicine belongs to a group of medicines called antibiotics called penicillins. It works by killing bacteria. Piperacillin is an antibiotic that kills many types of bacteria. Tazobactam belongs in the penicillin group but does not have activity against bacteria. It helps piperacillin to overcome bacteria which have become resistant to piperacillin. This medicine is active against bacteria which cause serious infections such as: • Chest infections • Urine infections • Stomach infections • Skin infections • Gynaecological infections • Septicaemia (blood poisoning). TAZOPIP is also used to treat many other infections. In hospitalised children aged 2 to 12 years, TAZOPIP is used to treat serious infections in the abdomen. TAZOPIP is not recommended to treat abdominal infections in children under 2 years. TAZOPIP will not work against infections caused by viruses such as cold or flu. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. This medicine is available only with a doctor's prescription. This medicine is not addictive. BEFORE YOU ARE GIVEN TAZOPIP _WHEN YOU MUST NOT RECEIVE_ _TAZOPIP_ DO NOT RECEIVE TAZOPIP IF YOU HAVE AN ALLERGY TO: • any medicine containing piperacillin, tazobactam, or any other penicillin a Lire le document complet
AUSTRALIAN PRODUCT INFORMATION TAZOPIP _piperacillin (as sodium) and tazobactam (as sodium) powder for injection _ _ _ 1 NAME OF THE MEDICINE Piperacillin (as sodium) and tazobactam (as sodium) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION TAZOPIP is an injectable antibacterial combination, consisting of the semisynthetic antibiotic piperacillin sodium and the beta-lactamase inhibitor tazobactam sodium, for intravenous administration. Each vial of TAZOPIP contains piperacillin and tazobactam 2 g/0.25 g or 4 g/0.5 g (as the sodium salts). The product contains no excipients or preservatives. 3 PHARMACEUTICAL FORM Powder for injection. TAZOPIP is available as a white to off-white sterile, cryodesiccated powder of piperacillin and tazobactam as the sodium salts packaged in glass vials. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS TAZOPIP for injection is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: • Lower respiratory tract infections • Urinary tract infections (complicated and uncomplicated) • Intra-abdominal infections • Skin and skin structure infections • Bacterial septicaemia • Gynaecological infections CHILDREN UNDER THE AGE OF 12 YEARS In hospitalised children aged 2 to 12 years, TAZOPIP for injection is indicated for the treatment of serious intra- abdominal infections. It has not been evaluated in this indication for paediatric patients below the age of 2 years. While TAZOPIP for injection is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin-resistant organisms. Appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to TAZOPIP. Therapy with TAZOPIP for injection may be initiated before results of such tests are known when there Lire le document complet